Woman Presents With a Brain Mass

The "New Developments in CAR T Treatments" webinar series brought together leading experts in the field of cancer immunotherapy to discuss the latest advancements and ongoing research in CAR T and natural killer cell therapies.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.

The NCCN guidelines have stated that osimertinib is the preferred category 1 treatment for patients with EGFR-mutated NSCLC discovered before the first line of therapy.

Data from the phase 3 OPERA trial support contact X-ray brachytherapy boost as a treatment option for preserving organs in smaller rectal adenocarcinoma tumors.